WO2012009426A1 - Préparation à haute tolérance pour nourrissons comprenant des protéines hydrolysées - Google Patents

Préparation à haute tolérance pour nourrissons comprenant des protéines hydrolysées Download PDF

Info

Publication number
WO2012009426A1
WO2012009426A1 PCT/US2011/043838 US2011043838W WO2012009426A1 WO 2012009426 A1 WO2012009426 A1 WO 2012009426A1 US 2011043838 W US2011043838 W US 2011043838W WO 2012009426 A1 WO2012009426 A1 WO 2012009426A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
hydrolyzed
carbohydrate
formula
infant
Prior art date
Application number
PCT/US2011/043838
Other languages
English (en)
Inventor
Chron-Si Lai
Paul W Johns
Steven R Davis
Hawley K Linke
Marlene W Borschel
Benjamin D Travis
Richard T Ponce Jr
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO2012009426A1 publication Critical patent/WO2012009426A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula

Definitions

  • the present disclosure relates to an improved tolerance infant formula. More particularly, the present disclosure relates to an improved tolerance infant formula including a hydrolyzed protein, a low glycemic carbohydrate, a substantially digestible fructose-containing carbohydrate, and a substantially indigestible fermentable carbohydrate.
  • Infant formulas are widely commercially available.
  • Conventional infant formulas typically contain fat, carbohydrate, protein, vitamins, and minerals, and potentially other nutritionally beneficial components.
  • Conventional infant formulas may be based on one of three general types of protein: (1) intact protein; (2) hydrolyzed protein; and/or (3) free amino acids.
  • hydrolyzed proteins such as hydrolyzed whey protein or hydrolyzed casein protein
  • hydrolyzed proteins can be used in infant formulas as an alternative to other proteins, in many cases the hydrolyzed protein is not well tolerated by the infant, especially when the hydrolyzed protein has a degree of hydrolysis of 7 or higher.
  • Intolerance is a non-immune system associated reaction and may be evidenced by behavior or stool or feeding pattern changes, such as increased spit-up or vomiting, an increased number of stools, more watery stools, black stools, and increased fussiness.
  • Intolerance is most often indicated by gastrointestinal symptoms (e.g., stool patterns and gas) as well as behavior characteristics (e.g., acceptance of formula, fussing and crying).
  • the present disclosure is directed to high tolerance infant formulas that include hydrolyzed protein.
  • the hydrolyzed protein is a hydrolyzed whey protein or hydrolyzed casein protein.
  • the infant formula improves tolerance and improves stool consistency and color.
  • the present disclosure is specifically directed to an infant formula comprising a low glycemic carbohydrate, a substantially digestible fructose-containing carbohydrate, a substantially indigestible fermentable carbohydrate, and a hydrolyzed protein, wherein the hydrolyzed protein comprises at least 50% by weight of the total protein and has a degree of hydrolysis of at least 7.
  • the present disclosure is further specifically directed to a method of decreasing the incidence of loose stool in an infant.
  • the method comprises administering to an infant a formula comprising a low glycemic carbohydrate, a substantially digestible fructose-containing carbohydrate, a substantially indigestible fermentable carbohydrate, and a hydrolyzed protein, wherein the hydrolyzed protein comprises at least 50% by weight of the total protein and has a degree of hydrolysis of at least 7.
  • the present disclosure is further specifically directed to a method of improving formula tolerance in an infant.
  • the method comprises administering to an infant a formula comprising a low glycemic carbohydrate, a substantially digestible fructose-containing carbohydrate, a substantially indigestible fermentable carbohydrate, and a hydrolyzed protein, the hydrolyzed protein comprising at least 50% by weight of the total protein and has a degree of hydrolysis of at least 7.
  • a hydrolyzed protein-containing high tolerance infant formula can be prepared by including a low glycemic carbohydrate, a substantially digestible fructose-containing carbohydrate, a substantially indigestible fermentable carbohydrate and a hydrolyzed protein, wherein the hydrolyzed protein comprises at least 50% by weight of the total protein.
  • the inclusion of the substantially indigestible fermentable carbohydrate in the formula substantially increased the tolerance of the hydrolyzed protein-containing formula.
  • the high tolerance infant formulas of the present disclosure generally comprise a low glycemic carbohydrate, a substantially digestible fructose-containing carbohydrate, a substantially indigestible fermentable carbohydrate, and hydrolyzed protein. Additionally, the high tolerance infant formulas generally comprise fat. These and other essential or optional elements or limitations of the high tolerance infant formulas and methods of the present disclosure are described in detail hereinafter.
  • infant formula refers to a nutritional composition designed for infants, including pre-term and full term infants up to one year in age, which contains sufficient nutrients such as proteins, carbohydrates, lipids, vitamins, and minerals to potentially serve as a supplemental, primary, or sole source of nutrition.
  • Numerical ranges as used herein arc intended to include every number and subset of numbers within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
  • the various embodiments of the high tolerance infant formulas of the present disclosure may also be substantially free of any optional or selected essential ingredient or feature described herein, provided that the remaining high tolerance infant formula still contains all of the required ingredients or features as described herein.
  • the term "substantially free” means that the selected high tolerance infant formula contains less than a functional amount of the optional ingredient, typically less than 0.1% by weight, and also including zero percent by weight of such optional or selected essential ingredient.
  • the high tolerance infant formulas and corresponding manufacturing methods of the present disclosure can comprise, consist of, or consist essentially of the essential elements and limitations of the disclosure as described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in the high tolerance infant formula.
  • the high tolerance infant formulas of the present disclosure may be formulated in any known or otherwise suitable product form for oral or parenteral administration, with powdered, ready-to-feed, and concentrated liquid formulations being particularly suitable.
  • Oral product forms arc preferred and include any solid, liquid, or powder formulation suitable for use herein, provided that such a formulation allows for safe and effective oral delivery of the essential and other selected ingredients from the selected product form.
  • the high tolerance infant formulas of the present disclosure may have any caloric density suitable for the targeted infants, or provide such a density upon reconstitution of a powder embodiment or upon dilution of a liquid concentrate embodiment.
  • caloric densities for the infant formula embodiments of the present disclosure are generally at least about 19 kcal/fl oz (660 kcal/liter), more typically from about 20 kcal/fl oz (675-680 kcal/liter) to about 25 kcal/fl oz (820 kcal/liter), even more typically from about 20 kcal/fl oz (675-680 kcal/liter) to about 24 kcal/fl oz (800-810 kcal/liter).
  • the 22-24 kcal/fl oz formulas are more commonly used in preterm or low birth weight infants, and the 20- 21 kcal/fl oz (675-680 to 700 kcal/liter) formulas are more often used in term infants.
  • the high tolerance infant formulas of the present disclosure include a low glycemic carbohydrate as part of the carbohydrate component of the formula.
  • low glycemic carbohydrate refers to carbohydrates that are slow digesting and cause a slower rise in blood sugar as compared to a glucose solution. Infants have a much less mature carbohydrate digesting system as compared to adults and a slow digesting carbohydrate for an infant may not be a slow digesting carbohydrate for an adult.
  • cooked starch is a low glycemic carbohydrate for infants, but not for adults.
  • GIP postprandial glucose dependent insulinotropic polypeptide
  • GIP has been suggested to act as a paracrine to induce Glucagon like peptides (GLP) secretion.
  • GLP-2 derived from GLP is an intestine gut maturation hormone.
  • GLP-1 another hormone derived from GLP is known to retard the transit of food through the gastrointestinal tract by reducing the amplitude of GI contraction, thus allowing more time for the infant to digest and absorb nutrients and improve tolerance by reducing spit-up and firming stools.
  • any low glycemic carbohydrate suitable for inclusion in infant formula can readily be utilized in the high tolerance infant formulas of the present disclosure.
  • Suitable examples of low glycemic carbohydrates include starch, cooked starch, rice starch, lightly hydrolyzed starch, dextrin, low dextrose equivalent (DE) maltodextrin, DEI maltodextrin, DE3 maltodextrin, lactose, galactose, and combinations thereof.
  • DE dextrose equivalent
  • the high tolerance infant formula includes the low glycemic carbohydrate in an amount of from about 10% (by weight) to about 40% (by weight), including from about 20% (by weight) to about 40% (by weight), and also including about 30% (by weight) of the total carbohydrate component in the high tolerance formula.
  • the high tolerance infant formulas of the present disclosure include a substantially digestible fructose-containing carbohydrate as part of the carbohydrate component of the formula.
  • any substantially digestible fructose-containing carbohydrate suitable for inclusion in infant formula can readily be utilized in the high tolerance infant formulas of the present disclosure.
  • Suitable examples of substantially digestible fructose-containing carbohydrate suitable for inclusion in infant formula can readily be utilized in the high tolerance infant formulas of the present disclosure.
  • carbohydrates include fructose, high fructose corn syrup, sucrose, palatinose and other sucrose isomers, and combinations thereof.
  • the high tolerance infant formula includes the substantially digestible fructose- containing carbohydrate in an amount of from about 5% (by weight) to about 40% (by weight), including from about 5% (by weight) to about 15% (by weight), and also including about 10% (by weight) of the total carbohydrate component in the high tolerance formula.
  • the high tolerance infant formulas of the present disclosure include a substantially-indigestible fermentable carbohydrate as part of the carbohydrate component of the formula.
  • substantially-indigestible fermentable carbohydrates have traditionally been thought to increase loose stool in infants, it has been surprisingly discovered that when used in combination with the other components as described herein, the substantially-indigestible fermentable carbohydrate actually increases the firmness of the stool of the infant.
  • the substantially-indigestible carbohydrate is generally selected from the group consisting of long chain fructooligosacchandes, short chain fructooligosacchandes (generally referred to as fructooligosacchandes), galactose-containing oligosaccharides (generally referred to as galactooligosaccharides), inulin, hydrolyzed inulin, gum arabic, and combinations thereof.
  • Fructooligosacchandes which are also known as fructooligosaccharide- bascd prebiotics, are saccharides comprising ⁇ -l inked fructose units, which are preferably linked by ⁇ (2,1) and/or ⁇ (2,6) glycosidic linkages.
  • suitable fructooligosaccharidcs include inulin, levari, and graminan.
  • inulin, levan, and graminan differ in the amount of branching that is present in their fructose chains and in the types of bonds connecting the individual ructose units.
  • levans generally consist of chains of fructose units that are typically connected by a ⁇ (2-6) bond. Although levans may occur as linear chain
  • fructooligosacchandes may be short chain fructooligosacchandes, long chain
  • fructooligosacchandes or combinations of short chain and long chain fructooligosaccharidcs.
  • Fructooligosaccharidcs may be found widely distributed in nature.
  • inulin may be found as a plant storage carbohydrate, and is common to plants of the Composite family.
  • Inulin may be derived from a variety of plants, such as Jerusalem artichoke and Dahlia tuber, and is a major constituent of some herbs, such as burdock root, dandelion root,
  • Fructooligosacchandes are also commercially available as, for example, Raftilose® (Orafti), Ac ti light (Beghin-Meiji), or Synergy 1® (Orafti) among others.
  • the fhictooligosaccharide of the present disclosure will typically have a degree of polymerization of from 2 to about 20.
  • the fructooligosaccharide has a degree of polymerization of from 2 to about 10, or even from 2 to 7. It should be understood that not all fructooligosaccharidcs present in a composition of the present disclosure need to have the same degree of polymerization.
  • the term "fructooligosaccharide” or "FOS" may also refer to a mixture of fructooligosaccharides having varying chain lengths; that is, long chain lengths and/or short chain lengths.
  • galactooligosaccharides are indigestible oligosaccharides containing one or more galactose molecule and one molecule of glucose connected through ⁇ (1,4) and/or ⁇ l,6) glycosidic bonds.
  • the GOS used in the compositions of the present disclosure may be selected from ⁇ -galactooligosaccharides, a-galactooligosaccharides, and (arabino-) galactans.
  • the GOS may be a trans-galactooligosaccharide (TOS).
  • the GOS may be represented by the formula: [galactose] justify-glucose, wherein n is an integer between 1 and 20, and preferably is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • the term "galactooligosaccharide” or “GOS” may also refer to a mixture of galactooligosaccharides having different chain lengths; that is, long chain lengths and/or short chain lengths.
  • Galactooligosaccharides are also commercially available as, for example, Vivinal® GOS (75% total solids, 60% of total solids GOS; Friesland) and GOS (Clasado).
  • the high tolerance infant formula includes the substantially-indigestible fermentable carbohydrate an amount of from about 1.4% (by weight) to about 15.0% (by weight), including from about 1.4% (by weight) to about 14.1% (by weight), and also including from about 2.0% to about 10.0% (by weight) of the total carbohydrate component in the high tolerance formula.
  • the high tolerance infant formulas of the present disclosure include a hydrolyzed protein as part of the protein component of the formula.
  • the hydrolyzed protein component of the high tolerance formula comprises at least 50% by weight, including at least 60% (by weight), including at least 70% (by weight), including at least 80% (by weight), including at least 90% (by weight) and also including 100% by weight of the total protein component of the high tolerance infant formula.
  • the hydrolyzed protein component of the high tolerance formula comprises hydrolyzed protein that has a degree of hydrolysis of at least 7, including at least 8, at least 9, at least 10, and including from 9-1 1.
  • the hydrolyzed protein included in the high tolerance formula is any hydrolyzed protein suitable for use in infant formulas including, for example, hydrolyzed whey protein, hydrolyzed casein protein, hydrolyzed soy protein, hydrolyzed wheat protein, hydrolyzed com protein, hydrolyzed fish protein, hydrolyzed vegetable protein, hydrolyzed pea protein, and combinations thereof.
  • hydrolyzed proteins include hydrolyzed whey protein, hydrolyzed casein protein, and combinations thereof.
  • hydrolyzed whey protein is a hydrolyzed sweet whey protein, such as that commercially available from Hilmar Ingredients (Hilmar, California) under the designation Hilmar 8350 Whey Protein Hydrolysate.
  • the high tolerance infant formulas of the present disclosure comprise carbohydrate, fat, and protein macronutrients of sufficient types and amounts, to meet the nutritional needs of infants, including premature infants.
  • macronutrients in the various embodiments of the present disclosure includes the ranges described hereinafter.
  • Proteins suitable for use in the high tolerance infant formulas of the present disclosure include hydrolyzed, partially hydrolyzed or non-hydrolyzed proteins or protein sources, and can be derived from any known or otherwise suitable source such as milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy), or combinations thereof.
  • the proteins for use herein can also include, or be entirely or partially replaced by, free amino acids known for use in nutritional compositions, non-limiting examples of which include tryptophan, glutamine, tyrosine, methionine, cysteine, arginine, and combinations thereof.
  • Nonprotein amino acids typically added to nutritional compositions include carnitine and taurine.
  • the D-forms of the amino acids are considered as nutritionally equivalent to the Informs, and isomer mixtures are used to lower cost (for example, D,L-methionine).
  • Fats suitable for use in the high tolerance infant formulas of the present disclosure include coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm and palm kernel oils, palm olein, canola oil, marine oils, cottonseed oils, long-chain polyunsaturated fatty acids such as arachidonic acid (ARA), docosahexacnoic acid (DHA), and eicosapentaenoic acid (EPA), and combinations thereof.
  • ARA arachidonic acid
  • DHA docosahexacnoic acid
  • EPA eicosapentaenoic acid
  • structured lipids may be incorporated into the high tolerance infant formulas.
  • Structured lipids are predominantly triacylglycerols containing mixtures of medium and long chain fatty acids on the same glycerol nucleus.
  • Carbohydrates in addition to carbohydrates described above may be included in the high tolerance infant formula. Additional carbohydrates suitable for use in the high tolerance infant formulas of the present disclosure may be simple, complex, or variations or combinations thereof.
  • suitable carbohydrates include hydrolyzed or modified starch or cornstarch, corn syrup, corn syrup solids, rice-derived carbohydrate, glucose, fructose, lactose, high fructose com syrup, indigestible oligosaccharides (e.g., fhictooligosaccharidcs), soluble or insoluble fiber, honey, sugar alcohols (e.g., maltitol, erythritol, sorbitol), and combinations thereof.
  • the concentration or amount of fat, protein, and carbohydrate in the high tolerance infant formulas of the present disclosure may vary considerably depending upon the particular product form (i.e., powder, ready-to-feed liquid, or concentrated liquid) and targeted dietary needs.
  • These macronutrients arc most typically formulated within any of the caloric ranges (embodiments A-F) described in the following table (each numerical value is preceded by the term "about”).
  • the high tolerance infant formula includes those embodiments in which the protein component may comprise from about 7.5% to about 25% of the caloric content of the formula; the carbohydrate component may comprise from about 35% to about 50% of the total caloric content of the infant formula; and the lipid component may comprise from about 30% to about 60% of the total caloric content of the infant formula
  • the protein component may comprise from about 7.5% to about 25% of the caloric content of the formula
  • the carbohydrate component may comprise from about 35% to about 50% of the total caloric content of the infant formula
  • the lipid component may comprise from about 30% to about 60% of the total caloric content of the infant formula
  • the high tolerance infant formulas may further comprise other optional components that may modify the physical, chemical, aesthetic or processing characteristics of the products or serve as pharmaceutical or additional nutritional components when used in a targeted population.
  • optional ingredients are known or otherwise suitable for use in nutritional products and may also be used in the compositions herein, provided that such optional ingredients are safe and effective for administration and are compatible with the essential and other selected components in the compositions.
  • Non-limiting examples of such other optional ingredients include preservatives, anti-oxidants, buffers, pharmaceutical actives, sweeteners, colorants, flavors, flavor enhancers, thickening agents and stabilizers, emulsifying agents, lubricants, and so forth.
  • the high tolerance infant formulas may further include one or more minerals, non-limiting examples of which include phosphorus, sodium, chloride, magnesium, manganese, iron, copper, zinc, iodine, calcium, potassium, chromium, chromium picolinate, molybdenum, selenium, and combinations thereof.
  • minerals non-limiting examples of which include phosphorus, sodium, chloride, magnesium, manganese, iron, copper, zinc, iodine, calcium, potassium, chromium, chromium picolinate, molybdenum, selenium, and combinations thereof.
  • the high tolerance infant formulas may also include one or more vitamins, non- limiting examples of which include carotenoids (e.g., beta-carotene, zcaxanthin, lutein, lycopene), biotin, choline, inositol, folic acid, pantothenic acid, choline, vitamin A, thiamine (vitamin Bl), riboflavin (vitamin B2), niacin (vitamin B3), pyridoxine (vitamin B6),
  • carotenoids e.g., beta-carotene, zcaxanthin, lutein, lycopene
  • biotin choline
  • inositol folic acid
  • pantothenic acid choline
  • vitamin A thiamine
  • vitamin Bl riboflavin
  • vitamin B3 niacin
  • pyridoxine vitamin B6
  • vitamin B12 cyanocobalamin
  • vitamin C ascorbic acid
  • vitamin D vitamin E
  • vitamin K various salts, esters or other derivatives thereof, and combinations thereof.
  • the high tolerance infant formulas of the present disclosure may be used to decrease the incidence of loose stool, gas, and/or spit up in infants that require, or benefit from, an infant formula including hydrolyzed protein due to allergies or other reasons.
  • the high tolerance infant formulas of the present disclosure may also be used to improve the color (i.e., less black stools) of an infant's stools.
  • the high tolerance infant formulas can be administered to any infant, preterm or full term, that can benefit from an infant formula including hydrolyzed protein that has high tolerance.
  • the present disclosure includes methods directed to decreasing the incidence of loose stools in an infant, particularly an infant that benefits from an infant formula based on hydrolyzed protein.
  • the method includes administering to the infant a formula including a low glycemic carbohydrate, a substantially digestible fructose-containing carbohydrate, a substantially indigestible fermentable carbohydrate, and a hydrolyzed protein, wherein the hydrolyzed protein comprises at least 50% by weight of the total protein and has a degree of hydrolysis of at least 7.
  • Particular infants that may benefit from this method include those infants with allergies related to cow's milk protein or protein other than hydrolyzed protein.
  • the present disclosure includes methods directed to improving infant formula tolerance in an infant, particularly an infant that benefits from an infant formula based on hydrolyzed protein.
  • the method includes administering to the infant a formula including a low glycemic carbohydrate, a substantially digestible fructose-containing
  • hydrolyzed protein comprises at least 50% by weight of the total protein and has a degree of hydrolysis of at least 7.
  • Particular infants that may benefit from this method include those infants with allergies related to cow's milk protein or protein other than hydrolyzed protein.
  • the high tolerance infant formulas of the present disclosure may be prepared by any known or otherwise effective technique suitable for making and formulating a powdered infant formula, a ready-to-feed infant formula, or a concentrated infant formula that is diluted prior to use, variations of which may depend upon variables such as the exact selected product form, ingredient combination, packaging and container selection, and so forth, for the desired high tolerance infant formula.
  • Such techniques and variations for any given formula are easily determined and applied by one of ordinary skill in the nutritional formulation or manufacturing arts based on the disclosure herein.
  • the high tolerance infant formulas of the present disclosure, including the exemplified formulas described hereinafter, can therefore be prepared by any of a variety of known or otherwise effective formulation or manufacturing methods.
  • aqueous slurry sometimes prepared from a number of preliminary slurries, containing carbohydrates, proteins, lipids, stabilizers or other formulation aids, vitamins, minerals, or combinations thereof.
  • the slurry is emulsified, pasteurized, homogenized, and cooled.
  • Various other solutions, mixtures, or other materials may be added to the resulting emulsion before, during, or after further processing.
  • This emulsion can then be further diluted, heat-treated, and packaged to form a ready-to-feed or concentrated liquid, or it can be heat-treated and subsequently processed and packaged as a reconstitutablc powder, e.g., spray dried, dry mixed, agglomerated.
  • Table 2 Formulation including hydrolyzed protein, sucrose and rice starch Ingredient Amount per 1000 lb 0b)
  • Table 3 Formulation including hydrolyzed protein, sucrose, rice starch and GOS
  • Examples 2-6 illustrate exemplary high tolerance infant formulas of the present disclosure, the ingredients of which are listed in Table 5 below. All ingredient amounts are listed as pounds per ⁇ 1000 pound batch of product, unless otherwise specified.
  • the high tolerance infant formulas of Examples 2-6 may be prepared according to conventional processing techniques as described herein.
  • the two week old piglets were randomized and housed in individual metabolic cages on day 1. During this adaptation period (7 days), the piglets were fed a commercial highly hydrolyzed protein based infant formula dispensed in a spill proof container. The piglets were fed three times a day and they are given 30 minutes to consume the feed. The feed was then removed after 30 minutes. The piglets were fed the two study formula for 2 weeks after the adaptation an training period (Table 6 and 7). Daily feed intake was recorded and the stool consistencies were recorded by the pig handlers.
  • the stools were analyzed for the following characteristics: percentage of watery stool, percentage of loose or mushy stool, percentage of soft stools, percentage of formed stool, and percentage of hard stools.
  • the mean rank stool consistency was also calculated (average of averaged daily stool score). The results are shown in Table 8.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des préparations à haute tolérance pour nourrissons comprenant des protéines hydrolysées, telles que des protéines de lactosérum hydrolysées et des protéines de caséine hydrolysées. Ces préparations à haute tolérance réduisent l'incidence de selles liquides et décolorées chez des nourrissons et peuvent également réduire les gaz et les régurgitations. Les préparations à haute tolérance comprennent une protéine hydrolysée, un glucide à faible indice glycémique, un glucide contenant du fructose sensiblement digestible et un glucide fermentescible sensiblement non digestible. L'invention concerne également des procédés d'utilisation de ladite préparation à haute tolérance pour nourrissons.
PCT/US2011/043838 2010-07-13 2011-07-13 Préparation à haute tolérance pour nourrissons comprenant des protéines hydrolysées WO2012009426A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36367810P 2010-07-13 2010-07-13
US61/363,678 2010-07-13

Publications (1)

Publication Number Publication Date
WO2012009426A1 true WO2012009426A1 (fr) 2012-01-19

Family

ID=44486954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/043838 WO2012009426A1 (fr) 2010-07-13 2011-07-13 Préparation à haute tolérance pour nourrissons comprenant des protéines hydrolysées

Country Status (1)

Country Link
WO (1) WO2012009426A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103750310A (zh) * 2014-01-03 2014-04-30 吉林修正修元生物科技有限公司 一种补钙、促进钙吸收的植物钙及其制备方法
EP3740087B1 (fr) 2018-01-16 2022-05-18 FrieslandCampina Nederland B.V. Formule hypoallergénique pour nourrissons et son procédé de préparation
CN115190765A (zh) * 2020-02-27 2022-10-14 雅培制药有限公司 改进骨健康的方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1112006A2 (fr) * 1998-05-01 2001-07-04 Abbott Laboratories Formule nutritive liquide complete administree per os
WO2001056406A1 (fr) * 2000-02-04 2001-08-09 Abbott Laboratories Nouvelle formule pediatrique et procedes servant a assurer la nutrition et a ameliorer la tolerance
US6306908B1 (en) 1997-02-21 2001-10-23 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
WO2002015719A2 (fr) * 2000-08-22 2002-02-28 Société des Produits Nestlé S.A. Compositions alimentaires
US20030118703A1 (en) 2001-12-12 2003-06-26 Nguyen Minhthy Le Methods and compositions for brightening the color of thermally processed nutritionals
WO2006130204A1 (fr) * 2005-06-01 2006-12-07 Bristol-Myers Squibb Company Formule pour nourrisson partiellement hydrolysée et à faible teneur en lactose
WO2006130200A1 (fr) * 2005-06-01 2006-12-07 Bristol-Myers Squibb Company Procedes de production d'hydrolysats partiels de proteines et preparations pour nourrissons contenant ces hydrolysats
WO2007004878A2 (fr) * 2005-07-01 2007-01-11 N.V. Nutricia Nutrition du nourrisson avec des proteines hydrolysees
WO2007073187A1 (fr) * 2005-12-20 2007-06-28 N.V. Nutricia Composition de glucides pour reponse plate au glucose
WO2008054192A1 (fr) * 2006-11-02 2008-05-08 N.V. Nutricia Utilisation de compositions alimentaires pour éviter des maladies
CN101322512A (zh) * 2008-06-16 2008-12-17 南京郁氏农牧开发有限公司 仔猪代乳料

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306908B1 (en) 1997-02-21 2001-10-23 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
EP1112006A2 (fr) * 1998-05-01 2001-07-04 Abbott Laboratories Formule nutritive liquide complete administree per os
US6589576B2 (en) 2000-02-04 2003-07-08 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
WO2001056406A1 (fr) * 2000-02-04 2001-08-09 Abbott Laboratories Nouvelle formule pediatrique et procedes servant a assurer la nutrition et a ameliorer la tolerance
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
WO2002015719A2 (fr) * 2000-08-22 2002-02-28 Société des Produits Nestlé S.A. Compositions alimentaires
US20030118703A1 (en) 2001-12-12 2003-06-26 Nguyen Minhthy Le Methods and compositions for brightening the color of thermally processed nutritionals
WO2006130204A1 (fr) * 2005-06-01 2006-12-07 Bristol-Myers Squibb Company Formule pour nourrisson partiellement hydrolysée et à faible teneur en lactose
WO2006130200A1 (fr) * 2005-06-01 2006-12-07 Bristol-Myers Squibb Company Procedes de production d'hydrolysats partiels de proteines et preparations pour nourrissons contenant ces hydrolysats
WO2007004878A2 (fr) * 2005-07-01 2007-01-11 N.V. Nutricia Nutrition du nourrisson avec des proteines hydrolysees
WO2007073187A1 (fr) * 2005-12-20 2007-06-28 N.V. Nutricia Composition de glucides pour reponse plate au glucose
WO2008054192A1 (fr) * 2006-11-02 2008-05-08 N.V. Nutricia Utilisation de compositions alimentaires pour éviter des maladies
CN101322512A (zh) * 2008-06-16 2008-12-17 南京郁氏农牧开发有限公司 仔猪代乳料

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 21 June 2010 (2010-06-21), XP002657928, Database accession no. 2010:760230 *
DATABASE WPI Week 200904, Derwent World Patents Index; AN 2009-A81786, XP002657927 *
SAVINO F ET AL: "Reduction ofcrying episodes owing the infantile colic: a randomized controlled study on the efficacy of a new infant formula", EUROPEAN JOURNAL OF CLINICAL NUTRITION, NATURE PUBLISHING GROUP, GB, vol. 60, 1 January 2006 (2006-01-01), pages 1304 - 1310, XP002623529, ISSN: 0954-3007, [retrieved on 20060531], DOI: 10.1038/SJ.EJCN.1602457 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103750310A (zh) * 2014-01-03 2014-04-30 吉林修正修元生物科技有限公司 一种补钙、促进钙吸收的植物钙及其制备方法
CN103750310B (zh) * 2014-01-03 2015-05-20 吉林修正修元生物科技有限公司 一种补钙、促进钙吸收的植物钙及其制备方法
EP3740087B1 (fr) 2018-01-16 2022-05-18 FrieslandCampina Nederland B.V. Formule hypoallergénique pour nourrissons et son procédé de préparation
US11903392B2 (en) 2018-01-16 2024-02-20 Frieslandcampina Nederland B.V. Hypoallergenic infant formula and methods for preparing the same
CN115190765A (zh) * 2020-02-27 2022-10-14 雅培制药有限公司 改进骨健康的方法

Similar Documents

Publication Publication Date Title
EP2230940B1 (fr) Composition nutritionnelle entérale liquide riche en énergie
CA2648826C (fr) Formule pour prematures
CN101568361A (zh) 营养组合物用于预防疾病的用途
JPH1118725A (ja) 糖尿病患者用栄養組成物
CN102238947A (zh) 营养组合物
US20140199431A1 (en) Liquid transition nutrition for infants
CA2758889A1 (fr) Emulsions nutritionnelles riches en fibres
JP2012523840A (ja) 血糖調節のための高繊維栄養エマルジョン
US20110129573A1 (en) Soy Protein-Based Nutritional Formula with Superior Stability
US20140308393A1 (en) Reduced calorie infant formulas containing specific whey to casein ratios
US20140377404A1 (en) Use of specific carbohydrate systems during pregnancy for effecting the offspring
WO2012009426A1 (fr) Préparation à haute tolérance pour nourrissons comprenant des protéines hydrolysées
US9345727B2 (en) Nutritional compositions containing a peptide component and uses thereof
MX2011010936A (es) Emulsiones nutricionales con un contenido elevado de fibras con glicerina.
TW201431502A (zh) 用於促進飽足的營養組成物
TW201420017A (zh) 營養奶精組成物
US20220096524A1 (en) Methods of promoting healthy catch-up growth
US20160029679A1 (en) Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women
EP2614724A1 (fr) Utilisation de systèmes de carbohydrates spécifiques pendant la grossesse pour réduire les effets nocifs sur la santé plus tard dans la progéniture
EP2614725A1 (fr) Utilisation de systèmes de carbohydrates spécifiques pendant la grossesse pour améliorer le développement et la formation de masse corporelle maigre et réduire les effets nocifs sur la santé plus tard dans la progéniture
AU2011100140A4 (en) Infant formula: DHA-ARA Ratio
US20100260917A1 (en) High Fiber Nutritional Emulsions for Blood Glucose Control
WO2021173997A9 (fr) Méthodes d'amélioration de la santé osseuse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11740759

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11740759

Country of ref document: EP

Kind code of ref document: A1